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ABSTRACT: N-Myristoyltransferase (NMT) covalently at-
taches a C14 fatty acid to the N-terminal glycine of proteins
and has been proposed as a therapeutic target in cancer. We
have recently shown that selective NMT inhibition leads to
dose-responsive loss of N-myristoylation on more than 100
protein targets in cells, and cytotoxicity in cancer cells. N-
myristoylation lies upstream of multiple pro-proliferative and
oncogenic pathways, but to date the complex substrate
speciﬁcity of NMT has limited determination of which diseases
are most likely to respond to a selective NMT inhibitor. We
describe here the phenotype of NMT inhibition in HeLa cells
and show that cells die through apoptosis following or
concurrent with accumulation in the G1 phase. We used quantitative proteomics to map protein expression changes for
more than 2700 proteins in response to treatment with an NMT inhibitor in HeLa cells and observed down-regulation of
proteins involved in cell cycle regulation and up-regulation of proteins involved in the endoplasmic reticulum stress and unfolded
protein response, with similar results in breast (MCF-7, MDA-MB-231) and colon (HCT116) cancer cell lines. This study
describes the cellular response to NMT inhibition at the proteome level and provides a starting point for selective targeting of
speciﬁc diseases with NMT inhibitors, potentially in combination with other targeted agents.
N-myristoylation is the irreversible attachment of a C14 fatty
acid to the N-terminal glycine of a protein, catalyzed by
myristoyl CoA: protein N-myristoyltransferase (NMT).1,2
Although the majority of N-myristoylation occurs cotransla-
tionally, we recently identiﬁed at least 30 proteins that are
myristoylated post-translationally during apoptosis, where
cleavage of proteins by caspases reveals a new N-terminal
glycine.3 N-myristoylation has been shown to be important for
the viability and survival of many organisms, including plants,
parasites, and humans, and NMT is an actively investigated
therapeutic target in parasite and fungal infections.4−14 In
humans, the two homologues of NMT, HsNMT1 and
HsNMT2,15 are potential chemotherapeutic targets in cancer
and autoimmune disorders16 and have been shown to be up-
regulated in several cancers.2,17,18 Chemical proteomic
approaches19 have recently revolutionized the ability to proﬁle
the substrates of lipid transferases such as NMT in cells and in
intact vertebrates,20 enabling new approaches for drug target
discovery and validation based on complete and quantitative
knowledge of the response of the lipidated proteome to
transferase inhibitors in vivo.
We recently characterized a selective HsNMT inhibitor
(compound 1, Figure 1A), a molecule originally discovered as
an inhibitor of Trypanosoma brucei NMT, as a tool to study
NMT inhibition in mammalian cells.3 We demonstrated that
this compound acts on-target in HeLa cells, causing dose-
dependent inhibition of N-myristoylation that is cytotoxic in a
time-dependent manner. Interestingly, HeLa cells maintain a
“plateau” of residual metabolic activity (approximately 25% of
untreated levels) following 3 days of inhibition even in the
presence of concentrations of inhibitor 1 (from 1 μM to 10
μM) that deliver complete inhibition of N-myristoylation in
cells (Supporting Information Figure 1). This plateau drops
with extended exposure, resulting in complete killing of HeLa
cells following 7 days of exposure. Using a chemical proteomic
method, we generated comprehensive and quantitative proﬁles
of NMT substrates, and their response to NMT inhibition; a
total of 70 cotranslational and 30 post-translational NMT
substrates were identiﬁed in HeLa cells,3 and similar analyses
were subsequently applied to other cell lines and an intact
vertebrate organism.20 These substrates encompass a rich
variety of functions in cells; N-myristoylation is known to be
important for localization and function in some cases, such as
the proto-oncogene c-Src,21 AMP-dependent kinase,22 or 26S
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proteasome regulatory subunits.23,24 Several substrates have
also been linked to cancer progression such as nucleolar protein
3, whose overexpression has been associated with cancer cell
resistance to apoptosis.25 These results suggest that inhibition
of N-myristoylation aﬀects multiple biological pathways,
ultimately resulting in cell death in cancer cell lines.
In recent years, quantitative proteomics has become a
powerful tool to study the mode of action of drugs26,27 since it
provides a relatively unbiased assessment of functional changes
occurring at the protein level and takes into account important
functional alterations such as changes in post-translational
events or protein degradation rate that are not directly
accessible to nucleic acid sequencing technology.26 A
quantitative proteomics approach could be particularly
informative for determining the mode of action for inhibition
of an enzyme with multiple substrates and that thus induces
multiple simultaneous downstream eﬀects. In this study, we
applied quantitative proteomics to study proteome level eﬀects
of NMT inhibition on HeLa cells, characterize the cytotoxic
phenotype, and identify top-level pathways that are modulated
by NMT inhibition. These data provide a starting point for
future studies to decipher the mode of action of NMT
inhibitors in speciﬁc disease contexts and for validation of
human NMT as a therapeutic target through identiﬁcation of
sensitive disease subtypes or novel drug combinations.
■ RESULTS
NMT Inhibition Impacts Cell Cycle through G1 Arrest.
We sought to investigate the response of cancer cells to
compound 1 in more detail to aid understanding of the
mechanism of action of this selective NMT inhibitor. The eﬀect
of NMT inhibition on cell proliferation and apoptosis was
evaluated in HeLa cells treated with various concentrations of
inhibitor 1 or with vehicle (DMSO) for 1, 3, or 7 days. 0.2 μM
inhibitor 1 corresponds to the EC50 value measured by a
standard metabolic activity (MTS) assay.3 As demonstrated by
previous tagging analyses, 0.2 μM and 1 μM inhibitor
correspond to concentrations suﬃcient to inhibit 50% and
90% NMT activity in HeLa cells, while treatment with 5 μM or
10 μM results in undetectable NMT activity in cells.3 Complete
NMT inhibition results in the previously observed plateau of
residual metabolic activity in an MTS assay after 3 days
(Supporting Information Figure 1). After 1 day, samples treated
with 1, 5, or 10 μM inhibitor displayed a signiﬁcant G1
accumulation (p < 0.01; Figure 1B and C). After 3 days, a
substantial proportion of cells treated with 1 μM or greater
Figure 1. NMT inhibition induced G1 arrest in HeLa cells. (A) Structure of compound 1. (B) Representative DNA content analysis for treatment
with DMSO (vehicle) or 1 μM inhibitor 1 for 1, 3, or 7 days. DNA was stained with propidium iodide (PI) and DNA content determined by ﬂow
cytometry. Number of cells was plotted against the PI ﬂuorescence intensity. (C) Cell cycle analysis (n = 3 biological replicates, SEM < 10%) across
a range of inhibitor concentrations and time points. The data were analyzed with FlowJo. (D) Flow cytometry experiment of cells treated with
bromodeoxyuridine (BrdU) and PI following treatment with DMSO or inhibitor 1 (5 μM) for 1 or 3 days.
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inhibitor concentration were sub-G1 (dead/apoptotic), with
the remainder mainly arrested in the G1 phase. Following 7
days of inhibition, cells were mostly dead/apoptotic (sub-G1)
in samples treated with >1 μM of inhibitor, whereas ca. 40% of
cells treated with 0.2 μM inhibitor were dead after 7 days,
consistent with the MTS assay (Supporting Information Figure
1). These ﬁndings suggest that upon NMT inhibition cells
undergo G1 arrest followed by cell death. Selective NMT
inhibition is characterized by a progressive onset of cytotoxicity,
and we hypothesized that this is due to the time required to
turn over existing N-myristoylated proteins in cells, concurrent
with evolution of the proteome toward a predominance of
nonmyristoylated NMT substrates. To conﬁrm the observed
cell cycle arrest phenotype, cells were stained with BrdU/PI
and analyzed by ﬂow cytometry (Figure 1D and Supporting
Information Figure 2). BrdU staining after 1- and 3-day
treatments with inhibitor 1 indicated a substantial decrease in
DNA synthesis, conﬁrming that cells arrested.
NMT Inhibition Induces Apoptotic Cell Death in a
Speciﬁc Time Frame. To investigate the mode of cell death,
markers of apoptosis were analyzed by Western blot in HeLa
cells treated for 1, 3, or 7 days with inhibitor 1 (Figure 2A).
Staurosporine (STS), a nonspeciﬁc kinase inhibitor known to
induce apoptosis,28 was used as a positive control for apoptosis,
and HsNMT1, which was previously shown to be cleaved
during apoptosis,29 was also assessed. Markers of apoptosis did
not change after 1 day of inhibition in agreement with cell
cytotoxicity3 and cell cycle analyses (Figure 1C). However, at 3
days treatment, PARP, BID, Caspase 3, and HsNMT1 were all
cleaved to a substantial extent. After 7 days of inhibition, it
proved diﬃcult to detect full length or cleaved PARP,
HsNMT1, and Caspase 3, probably because of complete
degradation. These results suggested that HeLa cells were dying
at least in part through apoptosis.
An annexin V-FITC/PI dual staining assay was used to
conﬁrm whether inhibitor 1 could induce apoptosis in HeLa
cells (Figure 2B and Supporting Information Figure 3).
Treatment with inhibitor 1 showed that annexin-V-positive
cells increased in a time-dependent manner in response to
NMT inhibition. Early apoptotic cells appeared after 24 h
treatment, consistent with relocation of phosphatidylserine
being a relatively early event in the apoptotic cascade. There
was a substantial population of dead cells observed after 3 days
of treatment, and all cells stained positive for annexin V after 7
days of treatment, consistent with cell cycle analysis (Figure
1C) and MTS assay. Thus, taken together, data in Figure 2
suggest that cells die in response to NMT inhibition through
apoptosis.
A potentially important NMT substrate for the mode of
action of cytotoxicity is the proto-oncogene c-Src, which is a
validated target for cancer therapy.30 Src family kinase
inhibitors, such as dasatinib, can induce apoptosis and a G1
arrest as observed in the context of NMT inhibition, while high
levels of c-Src tyrosine kinase activity have been associated with
cancer progression, where they promote cell survival,
proliferation, and metastasis.31 N-myristoylation is required
for the autophosphorylation of c-Src and, as a consequence, for
its tyrosine kinase activity.21 Upon NMT inhibition, we
observed a decrease of phosphorylated c-Src after 1 day and
3 days, suggesting that c-Src had a reduced protein kinase
activity, while levels of total c-Src remained constant
(Supporting Information Figure S4). However, while c-Src is
an interesting downstream target, we have previously shown
that NMT has over 100 protein substrates in mammalian cells,
and it is thus reasonable to suppose that additional proteins and
pathways will be linked to the mode of action of NMT
inhibition.
Figure 2. Prolonged NMT inhibition induces apoptosis in HeLa cells. (A) Western blot analysis of apoptotic markers in HeLa cells treated for 0, 1,
3, or 7 days with 5 μM inhibitor 1. Cells were treated with staurosporine (STS) (1 μM) for 4 h as a control for apoptosis. (B) Flow cytometry
analyses of cells treated with Annexin V and PI following treatment with inhibitor 1.
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Global Analysis of Temporal Proteome Dynamics in
Response to NMT Inhibition. We next sought to determine
the progressive eﬀects of NMT inhibition on key pathways in
cells through whole proteome analysis. NMT inhibition induces
negligible toxicity at 1 day, and we hypothesized that early
mechanism-related changes in protein abundance might occur
by 2 days, while after 3 days proteins aﬀected by the inhibitor
would reﬂect cell death pathways. We have previously shown
that after 1-day treatment with inhibitor 1,3 the abundance of
the large majority of proteins is not signiﬁcantly aﬀected. We
thus performed a quantitative analysis of the proteome
following treatment of HeLa cells with 1 (5 μM) for 0, 1, 2,
Figure 3. Quantitative proteomics and pathway analyses of NMT inhibited HeLa cells. (A) Dynamic proﬁle of signiﬁcantly altered protein levels.
Cells were treated with DMSO control or inhibitor 1 (5 μM for 1, 2, or 3 days), and >1100 proteins were quantiﬁed across the four samples (n = 3
biological replicates).3 Proteins for which abundance is signiﬁcantly aﬀected after 3 days of treatment and with a Log2 fold change >1 are shown
(ANOVA, FDR < 0.05, s0 = 1). Red indicates signiﬁcantly down-regulated proteins and blue signiﬁcantly up-regulated proteins. (B) Volcano plot of
log2 ratios representing log2 fold change of 3-day treatment to control, with lysate fractionation to increase proteome coverage (>3000 proteins
quantiﬁed, n = 3 biological replicates). Dashed lines represent t test signiﬁcance cutoﬀ (Benjamini−Hochberg FDR 0.02, s0 of 1). A total of 398
proteins are diﬀerentially expressed at 3 days. Red indicates signiﬁcantly down-regulated proteins. Blue shows signiﬁcantly up-regulated proteins, and
gray represents all other proteins. (C) GO annotations (biological process and cellular compartment) of proteins signiﬁcantly up- and down-
regulated after 3-day treatment, obtained from ClueGO and Cytoscape. The term p-value and the percentage of associated genes are indicated.
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and 3 days using a Spike-in SILAC approach,32 which allows
quantitative comparison between multiple biological samples (n
= 3 biological replicates) without restricting conditions for the
experiment to media speciﬁc for isotopic labeling (Supporting
Information Table 1). HeLa cells grown in standard DMEM
media were treated with the inhibitor for 0−3 days and after
lysis samples were spiked with lysate obtained from HeLa cells
grown in media containing heavy Lys and Arg. Tryptic
digestion of the samples using ﬁlter-assisted sample preparation
(FASP)33 enabled quantiﬁcation of proteome-wide changes in
protein abundance, determined in 3-fold replicate experiments
at each of the four time points of inhibitor treatment on a high
resolution nanoLC-MS/MS platform. A total of 1160 proteins
were quantiﬁed in at least two replicates at each of the time
Figure 4. Proteome-wide expression changes upon NMT inhibition for 3 days in HeLa cells. Network analysis was performed with STRING and
biological processes analyzed with ClueGo+. The interaction network was visualized with Cytoscape, and the most signiﬁcantly enriched biological
process clusters are indicated. (A) Network of up-regulated proteins. (B) Network of down-regulated proteins.
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points (Supporting Information Table 1 and Figure S5), with
L/H ratios normalized to the median value in each sample.
Proteins with a fold-change ratio of at least 2 (ANOVA-test,
FDR < 0.05) after 3-day treatment compared to no treatment
(0 day) are presented in Figure 3A. Twenty proteins were
signiﬁcantly down-regulated, while 37 proteins were up-
regulated in response to NMT inhibition. Interestingly, the
same groups of proteins were consistently and progressively
down- or up-regulated over the course of the experiment,
suggesting a consistent mechanism operating over time; these
changes were strongest at 3 days, suggesting that the later time-
point is most suitable to identify signiﬁcantly aﬀected proteins.
In order to obtain deeper protein quantiﬁcation at 3 days,
proteins were subjected to FASP and tryptic peptides
fractionated by pipet-based strong anion exchange chromatog-
raphy34 prior to analysis by nanoLC-MS/MS. Three biological
replicates were analyzed in 3 fractions for each time point (0
and 3 day treatment), leading to 18 data sets with excellent
reproducibility between replicates (Pearson coeﬃcient 0.816 to
0.921, Supporting Information Figure S6). More than 3500
proteins were identiﬁed, and 2749 proteins were accurately
quantiﬁed in at least two replicates of both samples (Supporting
Information Figure S6 and Table 2). The H/L ratio was
normalized to the median over biological replicates, and the
resultant quantitative distribution of relative protein abundance
exhibited a broad spectrum of dynamics from −2.6 to +2.6 log2
fold change. In total, 398 diﬀerentially expressed proteins were
identiﬁed with >1.5-fold change (t test signiﬁcant, FDR = 0.02,
s0 = 1) in the treated sample compared to control (Figure 3B),
with 162 signiﬁcantly down-regulated and 236 signiﬁcantly up-
regulated by NMT inhibition.
NMT Inhibition Induces ER-Stress in HeLa Cells. A
combination of approaches was deployed to understand the
biological functions most aﬀected by NMT inhibition across
the 398 diﬀerentially expressed proteins. The Cytoscape
ClueGo plug-in (Figure 3C, Supporting Information Figure
S7−S9 and Table 3) allowed functional grouping and
visualization of nonredundant biological terms across the
network, while analysis of the network using STRING enabled
the main clusters of proteins to be obtained (Figure 4). NMT
inhibition most signiﬁcantly (p < 10−4) down-regulated
chromosome organization/condensation processes, consistent
with cell cycle arrest, and mitochondrial electron transport
(Figure 3C). The most signiﬁcantly (p < 10−10) up-regulated
biological processes encompassed Golgi vesicle transport and
the response to endoplasmic reticulum (ER) stress and
carboxylic acid metabolism. In particular, proteins involved in
activation of the unfolded protein response, protein N-
glycosylation, and the ER-nucleus signaling pathway were
strongly induced, including ER chaperone BiP,35 which plays a
central role in the folding and assembly of proteins, degradation
of misfolded proteins, and preservation of ER homeostasis. A
number of known BiP interacting proteins were also up-
regulated, including other chaperones (GRP170/HYOU1) or
cochaperones (DNAJC10), together with proteins involved in
protein quality control (e.g., Calreticulin). Interestingly, the
four other most signiﬁcantly up-regulated biological processes
are closely related to ER-stress. Notably, either activation of N-
glycolysation by addition of N-glycan precursor N-acetylglucos-
amine or gain of function of GFAT/GFPT1 (which was
overexpressed in the present study) were recently shown to
activate the ER-associated degradation (ERAD) pathway and
act as a protective mechanism by activating the clearance of
misfolded proteins.36
NMT inhibition also resulted in signiﬁcant up-regulation of
proteins involved in incorporation of amino acids during
protein translation, including aminoacyl-tRNA synthetases,
amino acid transporters and proteins involved in the machinery
of protein synthesis, such as tryptophantRNA ligase,
cytoplasmic (WARS), serinetRNA ligase, cytoplasmic
(SARS), or bifunctional glutamate/proline-tRNA ligase
(EPRS). This is consistent with induction of ER-stress, which
has recently been shown to result in an increase in translation,
and a potential mechanism for cell death.37,38 Interestingly, we
discovered signiﬁcant up-regulation of ﬁve t-RNA ligase
proteins, IARS, EPRS, GARS, AARS, and WARS, as well as
seven proteins involved in the unfolded protein response,
SEC31A, HSPA5, SRPR, AARS, GFPT1, HYOU1, and ASNS.
To conﬁrm induction of ER-stress following NMT inhibition,
we analyzed cell lysates from HeLa cells treated with inhibitor 1
for 0, 1, 3, and 7 days by Western blot (Figure 5) and found
that key markers of ER-stress, including BiP, Ero1-Lα, IRE1α,
PDI-1, and PERK were relatively up-regulated in this cell line
following NMT inhibition. Furthermore, CHOP, the pro-
apoptotic transcription factor of the unfolded protein response
(UPR), and proteins upstream of CHOP in the pro-apoptotic
pathway of the UPR (PERK, eIF2α and ATF4) were also up-
regulated (Figure 5), strongly suggesting that the UPR pathway
contributes to activation of apoptosis.
NMT inhibition also appears to impact pathways relevant to
ER to Golgi traﬃcking, a critical process involved in the sorting
of properly folded, processed, and assembled proteins from
unfolded or immature proteins, and from ER-resident
proteins.39 SEC23, SEC24, SEC13 and SEC31, SAR1a, and
the components of COPII, which are associated with ER to the
Golgi transport vesicles, are all up-regulated upon treatment
with inhibitor 1, as are COPII-associated proteins such as SLY1
(SCFD1) and melanoma inhibitory activity protein 3
(MIA3).40,41
Figure 5. NMT inhibition induces ER stress in HeLa cells. Western
blot analyses of markers of ER stress and unfolded protein response;
HeLa were treated with inhibitor 1 (5 μM) for 0, 1, 3, or 7 days.
Hsp90 was used as a loading control. Data are representative of at least
three biological replicates.
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NMT Inhibition Induces a Related Phenotype in Other
Cancer Cell Lines. As the proteome and myristoylated
proteome of HeLa cells have been previously well-charac-
terized, we initially employed this cell line to probe the mode of
action of inhibitor 1. In order to test the scope of this ﬁnding,
MTS assays and cell cycle analyses were carried out for 1 in
three additional cancer cell lines: MDA-MB-231 (breast
cancer), HCT-116 (colon), and MCF-7 (breast; Supporting
Information Figure 10A). The time-dependent response with
residual metabolic activity characteristic of on-target NMT
inhibition was found to be strongly conserved between these
lines, suggesting a conserved mode of action through NMT
inhibition. However, MDA-MB-231 and HCT-116 were not as
sensitive to 3-day NMT inhibition, showing residual metabolic
activities of 51% and 73%, respectively. MCF-7 also had a
diﬀerent pattern with a somewhat lower EC50 and a plateau of
metabolic activity at 64%. Following prolonged NMT
inhibition (7 days), treatment with 10 μM of inhibitor 1
resulted in cell death for all of these lines. In line with a
conserved mode of action, all ER-stress markers previously
probed in HeLa were also progressively up-regulated in all three
cell lines, following NMT inhibition over 1, 3, and 7 days
(Supporting Information Figure 10E).
Similarly to HeLa cells, MDA-MB-231, HCT-116, and MCF-
7 underwent G1 accumulation after 1−2 days (Supporting
Information Figure 10B−D). An increase in the number of
subG0/G1 cells was also observed after 3 days for MCF-7 and
MDA-MB-231 cells but not for HCT-116, suggesting that these
cells might be less sensitive to NMT inhibition. NMT
inhibition also induced apoptosis in MDA-MB-231, MCF-7,
and HCT-116 cells; however, induction was slower in HCT-
116, in agreement with the small sub G0/G1 population
observed in cell cycle analysis (Supporting Information Figure
10C). These variations in sensitivity between lines may result
from diﬀerential NMT substrate expression or NMT enzyme
activity, the particular importance of speciﬁc NMT substrates in
a given cell line, or diﬀerences in susceptibility to downstream
cell death pathways (e.g., apoptosis).
■ DISCUSSION
In the present study, in-depth quantitative proteomics analysis
was used to characterize the proteome-wide cellular response to
NMT inhibition, identifying 398 signiﬁcantly diﬀerentially
expressed proteins. These changes were distributed across
multiple important processes, with a substantial proportion
converging on pathways related to cell cycle regulation and ER
stress. The inhibitor used in the present study has been shown
to be a selective pharmacological tool for inhibition of NMT
activity in human cells.3 Although we cannot categorically
exclude a contribution from other targets, time-dependent
cytotoxicity as well as a strong correlation between dose-
dependent tagging of NMT substrate with YnMyr and dose-
dependent cytotoxicity in HeLa are highly consistent with on-
target and selective NMT inhibition in mammalian cells.3
ER-stress is a mechanism employed by cells to restore
normal function of the ER following accumulation of misfolded
proteins. Initially, proteins involved in protein folding or
degradation (the unfolded protein response (UPR) pathway)
are up-regulated, concurrent with an attenuation of translation
of protein involved in the cell cycle and a G1 arrest,42 in close
agreement with observations made in the present study. During
ER-stress, misfolded proteins are degraded in the ER associated
degradation (ERAD) pathway by the proteasome, or
alternatively by autophagy, which can act as a protective
mechanism by helping cells to cope with ER-stress.43 Several
proteins involved in autophagy were up-regulated in the present
study, including CTSD, GABARAPL2, LAMP1, MAP1LC3A,
MAP1LC3B, MAP1LC3B2, RAB1A, and SQSTM1. If ER
homeostasis is not restored, prolonged ER-stress will result in
apoptosis and/or autophagy, and cell death,44 and we observed
that selective inhibition of NMT in HeLa cells resulted in
progressive induction of ER stress and eventual cell death, at
least in part through apoptosis. Interestingly, induction of ER-
stress by tunicamycin, an N-glycosylation inhibitor widely
employed to promote ER-stress, resulted in a comparable
phenotype in neuroblastoma SH-SY5Y cells, with up-regulation
of ER chaperones (BiP), aminoacyl-tRNA synthases, and
proteins involved in protein transport, as well as induction of
apoptosis.45 NMT inhibition appeared to have a similar
phenotype (G1 accumulation, increasing cell death over time,
ER-stress) in a range of cancer cell lines, albeit with variations
in sensitivity (Supporting Information Figure S10).
With more than 70 diﬀerent proteins proven to be
cotranslationally myristoylated by NMTs in HeLa cells, NMT
inhibition is likely to aﬀect multiple pathways, several of which
could potentially trigger ER-stress. Notably, ADP-ribosylation
factors (ARFs) are N-myristoylated small GTPases essential for
COPI vesicle formation in retrograde protein transport from
Golgi to ER.46 N-myristoylation of ARF1 is required for
binding to phospholipid membranes and activation by guanine
nucleotide exchange factors (GEFs) that promote the exchange
of GDP for GTP.46,47 Inhibition of Golgi-speciﬁc Brefeldin A
resistance factor 1 (GBF1), the ARF guanine nucleotide-
exchange factor (GEF), by Brefeldin A prevents ARF activation
and COPI recruitment to membranes, resulting in accumu-
lation of proteins in the ER, ER-stress, and ﬁnally
apoptosis.46,48 Interestingly, GBF1 is also up-regulated in the
present study, consistent with its recently reported role in
responding to reduced ARF activity.49 Taken together, these
data suggest that ARFs merit future investigation as potentially
important NMT substrates for the cytotoxic mode of action of
NMT inhibitors. Arf1-targeted agents have recently been
reported with potent in vivo anticancer activity,50 and NMT
inhibition is likely to result in a mechanistically distinct but
functionally similar outcome by preventing Arf1 localization at
the Golgi.
One of the 26S regulatory proteasome subunits (PSMC1)
and four E3 ubiquitin ligases involved in the proteasome
degradation pathway (MGRN1, RNF125, ZNRF1, and
ZNRF2) are N-myristoylated, and ER-stress may also be
enhanced following malfunction of the proteasome machinery.
Indeed, Bortezomib A, a 26S proteasome inhibitor, is known to
induce ER-stress by overloading the ERAD pathway with
misfolded proteins.43 During ER-stress, degradation of
misfolded proteins by the proteasome (ERAD pathway) also
allows recycling of essential amino acids in cells, and it was
recently shown that proteasome inhibition can lead to cell
death through the failure of amino acid homeostasis.51 In this
context, it is particularly interesting that starvation response
processes were highly enriched (p < 10−4) upon NMT
inhibition.
It is also conceivable that NMT inhibition could result in
accumulation of excess free myristic acid as a result of lowered
ﬂux through the N-myristoylation pathway. Although longer
chain fatty acids have been observed to enhance ER-stress,52
this mechanism seems unlikely to contribute to the mode of
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action in cells since introduction of excess myristic acid is
minimally cytotoxic in comparison to longer chain fatty acids.53
■ CONCLUSION
The present study provides a resource to guide future targeting
of speciﬁc diseases with NMT inhibitors and a preliminary
study of the pathways aﬀected by an NMT inhibitor as a single
agent in cancer cells. While most of the pathways highlighted in
our whole proteome analysis may be important for phenotypes
other than cytotoxicity, we have shown that NMT inhibition
kills HeLa cells at least in part through the ER stress and UPR
pathways.
ER stress has been shown to be chronically activated in many
tumors, where it allows tumor cells to proliferate and survive
under extreme conditions such as hypoxia and protects them
from chemotherapy.54 Pharmacological ER stress can impose
an additional burden on this pro-survival pathway, activating
pro-apoptotic pathways and cell death. Several drugs promoting
ER-stress have already entered the clinic, or are in clinical trials,
such as Bortezomib A or Brefeldin A, discussed above.55
However, these compounds can either increase sensitivity or
resistance to anticancer therapies, depending on the inhibitor
and the cancer cell line.56 As both the proteasome and
autophagy are important in the response to ER-stress to
degrade unfolded proteins, it has been suggested that it might
be beneﬁcial to modulate these pathways simultaneously,56 and
NMT inhibitors oﬀer a novel combination of ER-stress
promoting mechanisms. In future studies it will be interesting
to test the hypothesis that cell lines dependent on chronic ER-
stress to survive will be particularly sensitive to NMT inhibition
as a single agent, subject to cell-line-speciﬁc susceptibility to
apoptosis. In contrast, normal and slowly proliferating cells that
lack pre-existing ER stress could be less susceptible.
Taken together, the data presented here suggest that NMT
inhibition progressively induces a unique and speciﬁc cell state
through alteration of pathways connected to its 100+ substrate
proteins. We have highlighted some of the most prominent
pathways aﬀected following extended inhibitor exposure, but it
is also clear that the inﬂuence of NMT inhibition is remarkably
subtle, with only 14% of the proteome signiﬁcantly modulated
after 3 days. We suggest that two complementary approaches
could be used in the future to unlock the potential of NMT
inhibitors for oncology indications: (1) wider screening of
cancer cell line panels to uncover unanticipated sensitivities for
speciﬁc cancer subtypes and (2) comparative proteomic
analysis of NMT substrate proﬁles and proteome changes in
contrasting or drug-resistant cell lines, to reveal sensitivity or
resistance mechanisms. We anticipate that deeper system level
analysis of these data sets will lead not only to novel indications
for human NMT inhibitors as single agents but also to
identiﬁcation of drug synergies that exploit the altered signaling
network induced by NMT inhibition to reverse resistance,
improve eﬃcacy, or extend the therapeutic index for agents
already in the clinic.
■ METHODS
General. In-gel ﬂuorescence was recorded using an ETTAN Dige
Imager (GE Healthcare). Chemiluminescence was recorded using a
LAS-3000 Imaging System (Fujiﬁlm). Absorbance in 96-well plates
was measured using a SpectraMax M2/M2e Microplate Reader from
Molecular devices. Culture media and reagents were obtained from
Sigma-Aldrich, Gibco (Life technologies) and A&E Scientiﬁc (PAA).
For quantitative proteomics (SILAC), R10K8 and R0K0 DMEM
media were purchased from Dundee cell products, and the cell
dissociation buﬀer (enzyme free, PBS-based) was obtained from Gibco
(Life Technologies). Dialyzed FBS was obtained from Sigma-Aldrich.
All buﬀers were ﬁltered using a 0.2 μM ﬁlter to prevent any
contamination. MTS assay was performed as previously described.3
Cell Culture. HeLa, MDA-MB-231, and MCF-7 cells were grown
in DMEM supplemented with 10% FBS and 1% penicillin/
streptomycin. HCT 116 cells were grown in McCoy’s 5a Medium
Modiﬁed supplemented with 0.22 g/L glutamine, 10% FBS, and 1%
penicillin/streptomycin. All cells were grown in a humidiﬁed 10%
CO2-containing atmosphere at 37 °C. Cells were plated 24 h before
treatments. The number of cells plated for each cell line can be found
in the Supporting Information.
Inhibitor 1 Treatment. Cells were incubated with inhibitor 1 (0,
1, or 5 μM) for 0−7 days before cell lysis (Western blot analysis), cell
ﬁxation (ﬂow cytometry experiments), or treatment with MTS (cell
cytotoxicity assay). The total amount of DMSO was normalized to the
maximum amount of DMSO used.
Western Blot. After treatment with inhibitor 1, cells were washed
with PBS (3×) and lysed on ice (lysis buﬀer for apoptosis samples:
PBS 1×, 0.1% SDS, 1% Triton X-100, 1 × EDTA-free complete
protease inhibitor (Roche Diagnostics), and lysis buﬀer for ER stress/
UPR samples: 100 mM tris at pH 7.4, 4% SDS, EDTA-free protease
inhibitor). Lysates were kept on ice for 20 min and centrifuged at
17 000g for 20 min to remove insoluble material. Supernatants were
collected and stored at −80 °C. Protein concentration was determined
using the Bio-Rad DC Protein Assay. Proteins were separated on an
SDS-PAGE gel and transferred to PVDF membranes (Millipore,
Immobilon-PSQ membrane, pore size 0.2 μM) or nitrocellulose
membranes (GE Healthcare, Hybond ECL, pore size 0.45 μM) using a
wet transfer setup and a Tris-glycine transfer buﬀer supplemented with
0.1% SDS and 10% MeOH. Membranes were washed with TBS-T (1
× TBS, 0.1% Tween-20), blocked (5% dried skimmed milk in TBS-T),
washed with TBS-T (3×), and then incubated with the appropriate
primary antibody [BiP (Cell Signaling Technology, 9956S), Ero1-Lα
(Cell Signaling Technology, 9956S), IRE1α (Cell Signaling Technol-
ogy, 9956S), PDI (Cell Signaling Technology, 9956S), PERK (Cell
Signaling Technology, 9956S), c-Src (Cell Signaling Technology,
2123), Tubulin (Santa Cruz, SC53646), pro-caspase 3 (Cell Signaling
Technology SC13156), NMT1 (Atlas Antibodies, HPA022963), BID
(Cell Signaling Technology 2002S), PARP (Santa Cruz, SC8007),
CHOP (Cell Signaling Technology, 2895), Hsp90 (Santa Cruz, sc-
69703), eIF2α (Cell Signaling Technology, 9722), phosphor-eIF2α
(Cell Signaling Technology, 9721), or ATF4 (Proteintech, 10835-1-
AP)] in blocking solution overnight, washed with TBS-T (4×, 10
min), incubated with the appropriate secondary antibodies in blocking
solution for 1 h (mouse: HRP goat anti mouse, 1/20 000, BD
Pharmingen, cat. no. 554002; rabbit: HRP goat anti rabbit, 1/5000,
Invitrogen, cat. no. G-21234) washed with TBS-T (4×, 10 min) and
developed with Luminata Crescendo Western HRP substrate
(Millipore) according to the manufacturer’s instructions and on a
Fujiﬁlm LAS 3000 imager.
Cell Cycle Analysis/PI Stain. After treatment with inhibitor 1 or
DMSO, both adherent and ﬂoating cells were harvested and washed
with PBS (2 × 1 mL). Cell pellets were resuspended in 70% EtOH and
ﬁxed overnight at 4 °C or for several days at −20 °C. Fixed cells were
washed with PBS (2 × 1 mL). Cell pellets were resuspended in PI
solution (200 μL, 50 μg/mL) and transferred to a 5 mL tube for ﬂow
cytometry analysis. A total of 10 μL of RNase was added to each tube.
Samples were quickly vortexed and incubated at RT in the dark prior
to analysis. Samples were processed using a BD LSRFortessa cell
analyzer (BD Biosciences, UK). The distribution of cells in each phase
of the cell cycle was calculated using FlowJo 7.6.5 software.
Annexin V/PI Analysis. Dead and apoptotic cells were detected
using an FITC Annexin V Apoptosis Detection Kit I (BD
Pharmingen) and the protocol described by the supplier with some
modiﬁcations.
After treatment with the inhibitor or DMSO, both adherent and
ﬂoating cells were harvested and washed with PBS (2 × 1 mL). Cell
pellets were resuspended in 200 μL of 1× binding buﬀer (1 × 106
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cells/mL). A total of 100 μL of the solution were transferred to a 5 mL
tube. A total of 5 μL of FITC Annexin V and 5 μL PI were added. The
samples were vortexed and incubated for 15 min at RT in the dark. A
total of 400 μL of 1× binding buﬀer was added to each tube prior to
analysis by ﬂow cytometry. Samples were analyzed within 1 h
following PI and Annexin V addition. Samples were processed using a
BD LSRFortessa cell analyzer (BD Biosciences, UK). Samples were
compensated automatically using untreated cells and unstained,
apoptotic cells (1 μM STS treatment for 6 h) stained with Annexin
V and dead cells (10 μM treated cells for 7 days) stained with PI.
The distribution of apoptotic, dead, and alive cells was calculated
using FlowJo 7.6.5 software.
BrdU/PI Stain. Cells were treated with BrdU (10 mM, GE
Healthcare) for 30 min before the end of the experiment. Both
adherent and ﬂoating cells were harvested and washed with PBS (1 ×
1 mL). Cell pellets were resuspended in 70% EtOH and ﬁxed
overnight at 4 °C or for several days at −20 °C. Fixed cells were
washed with PBS (1 × 1 mL) and collected by centrifugation. Cells
were resuspended in 2 M HCl/0.5% (v/v) Triton X-100 and
incubated at RT for 30 min.
Cells were collected by centrifugation, washed in 1 mL of
neutralizing solution (0.1 M Tris at pH 8.5), and collected once
more before addition of 1 mL of blocking solution (1% (w/v) BSA/
0.5% (v/v) Tween 20 in PBS). A total of 106 cells were transferred to a
Falcon tube and collected by centrifugation. Cells were resuspended
directly in a solution of the FITC-conjugated anti-BrdU antibody
(347583, BD Biosciences, 1 μL) in blocking solution (1% (w/v) BSA/
0.5% (v/v) Tween 20 in PBS, 19 μL) and incubated at RT in the dark
for 30 min. Cells were then washed with blocking solution and
collected by centrifugation. Cell pellets were resuspended in PI
solution (200 μL, 50 μg/mL) and transferred to a 5 mL tube for ﬂow
cytometry analysis. A total of 10 μL of RNase was added to each tube.
Samples were incubated at RT in the dark prior to analysis. FITC-
ﬂuorescence against PI ﬂuorescence using the FlowJo 7.6.5 software.
BrdU positive cells were scored as the population of cells with FITC-
ﬂuorescence higher than that of the G1 or G2/M population
Proteomics: Cells ± Inhibitor. Following treatment with
inhibitor 1 for 0, 1, 2, or 3 days (5 μM), adherent and ﬂoating cells
were lysed in 100 mM Tris at pH 7.4, 4% SDS, 0.1 M DTT EDTA-free
protease inhibitor. Protein concentration was determined, and the
samples were spiked-in with a heavy spike-in standard prepared by
lysing heavy HeLa cells in the same lysis buﬀer. The samples and
spike-in standard were mixed in a 1:1 ratio. Samples were digested
according to a Filter-Aided Sample Preparation (FASP) protocol,
which was performed using a 5 kDa molecular weight cutoﬀ ﬁlter
(EMD Millipore), according to Sharma et al.26 with modiﬁcations.
Brieﬂy, 30 μL of each sample (60 μg of lysate) was mixed with 200 μL
of 8 M urea in 100 mM Tris-HCl (pH 8.5; urea buﬀer) in the spin
ﬁlter and centrifuged at 14 000g for 15 min at 20 °C to remove SDS.
The centrifugation steps were repeated if the volume left in the ﬁlter
exceeded 50 μL. The proteins were washed with 200 μL of urea buﬀer
to exchange any remaining SDS by urea. The proteins were alkylated
with 100 μL of 50 mM iodoacetamide for 20 min at RT in the dark.
The proteins were washed with urea buﬀer (2 × 100 μL) and with 50
mM ammonium bicarbonate (pH 8.0; 5 × 200 μL). A total of 1 μg of
trypsin in 100 μL of 50 mM ammonium bicarbonate (pH 8.0) was
added to the proteins in the spin ﬁlter, and proteins were digested with
trypsin overnight at 37 °C. Peptides were eluted by centrifugation by
the addition of 40 μL of 50 mM ammonium bicarbonate (pH 8.0) and
of 50 μL of 0.5 M NaCl. Where indicated, samples were fractionated
to increase the number of identiﬁed proteins according to a published
protocol.34 Samples were acidiﬁed with TFA (1% (v/v) TFA) and
loaded on the sorbent and washed with 0.2% (v/v) TFA in Milli-Q
water (2 × 60 μL) to desalt the sample. Elution occurred from the
sorbent (SDB-RPS from 3M) with 60 μL of 100 mM ammonium
formate, 40% (v/v) ACN, and 0.5% (v/v) formic acid to give “fraction
1,” with 60 μL of 5% (v/v) ammonium hydroxide and 80% (v/v) ACN
to yield “fraction 2,” followed by elution with 60 μL 5% (v/v)
ammonium hydroxide and 80% (v/v) ACN to give “fraction 3.”
Fractions were concentrated and peptides dissolved in 0.5% TFA and
2% acetonitrile in water before being transferred into LC-MS sample
vials. Nonfractionated samples were desalted prior to LC-MS/MS
analysis according to a published protocol.57 Elution from the sorbent
(SDC-XC from 3M) with 70% acetonitrile in water was followed by
speed-vac-assisted solvent removal, reconstitution of peptides in 0.5%
TFA, and 2% acetonitrile in water and transferred into LC-MS sample
vials.
LC-MS/MS Analysis. The analysis was performed as previously
described3 using an Acclaim PepMap RSLC column (50 cm × 75 μm
inner-diameter; Thermo Fisher Scientiﬁc) using a 2 h acetonitrile
gradient in 0.1% aqueous formic acid at a ﬂow rate of 250 nL min−1.
Easy nLC-1000 was coupled to a Q Exactive mass spectrometer via an
easy-spray source (all Thermo Fisher Scientiﬁc). The Q Exactive was
operated in data-dependent mode with survey scans acquired at a
resolution of 75 000 at m/z 200 (transient time 256 ms). Up to 10 of
the most abundant isotope patterns with a charge of +2 or higher from
the survey scan were selected with an isolation window of 3.0 m/z and
fragmented by higher-energy collision dissociation (HCD) with
normalized collision energies of 25. The maximum ion injection
times for the survey scan and the MS/MS scans (acquired with a
resolution of 17 500 at m/z 200) were 20 and 120 ms, respectively.
The ion target value for MS was set to 106 and for MS/MS to 105,
and the intensity threshold was set to 8.3 × 102.
Proteomics Data Analysis. The data were processed with
MaxQuant version 1.3.0.5,58 and the peptides were identiﬁed from
the MS/MS spectra searched against the human Swissprot+Isoforms
database (July 2013) using the Andromeda search engine. Cysteine
carbamidomethylation was used as a ﬁxed modiﬁcation and
methionine oxidation as a variable modiﬁcation. Up to two missed
cleavages were allowed. “Unique and razor peptides” mode was
selected. The FDR was set to 0.01 for peptides, proteins, and sites.
Other parameters were used as preset in the software. Data were
analyzed using Microsoft Oﬃce Excel 2007 and Perseus version
1.3.0.4.
Analysis of the Nonfractionated Samples. The experiment
comprised three biological replicates for each sample (0 day treatment,
1 day treatment, 2 day treatment, 3 day treatment). The replicates
were grouped together. Ratios of light/heavy (L/H, corresponding to
the amount of protein in the lysate treated with the inhibitor for 0−3
days/amount of protein in the spike-in standard) found for each
protein, each condition, and each replicate (three biological replicates)
were determined by MaxQuant as explained above. The data were
ﬁltered to require at least two valid values in the “0 day treatment”
protein group. Ratios were logarithmized (base 2). L/H ratios were
normalized to the median value in each replicate. An ANOVA test was
performed to detect signiﬁcant changes between the four time points
(permutation based FDR statistics were applied (250 permutation,
FDR < 0.05, 2 tailed, s0 = 1). The data were ﬁltered to keep only
proteins which were signiﬁcantly up/down regulated based on the
ANOVA test. The data were further ﬁltered by keeping only the
proteins with a Log2 fold change higher than 1 (“up-regulated”
proteins) or lower than −1 (“down-regulated” proteins) after 3 days
(for protein with no valid value in the 3 day samples, the data were
manually inspected, and protein with a Log2 fold change higher than 1
(or lower than −1) after 2 days was added to the list of signiﬁcant
proteins). To get the Log2 fold change after 1 day treatment, 2 day
treatment, and 3 day treatment, the Log2 mean of L/H ratios for “0
day treatment” was subtracted from the mean of L/H ratios of the 1
day treatment, 2 day treatment, and 3 day treatment, respectively.
Analysis of the Fractionated Samples. For the fractionated
samples (three fractions/replicate, three biological replicate for each
sample (0 day treatment and 3 day treatment), 18 LC-MS runs in
total), fractions of a same biological replicate were combined using the
“set fractions” function in MaxQuant. The data were ﬁltered to require
at least one valid value. The replicates were grouped together. Ratios
of light/heavy (L/H, corresponding to amount of protein in the lysate
treated with the inhibitor for 0−3 days/amount of protein in the spike-
in standard) found for each protein, each condition, and each replicate
(three biological replicates) were determined by MaxQuant as
explained above. L/H ratios were normalized to the median value in
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each sample. A modiﬁed t test with permutation based FDR statistics
was applied (“two-sample test,” FDR of 0.02, s0 = 1) between the two
groups. Protein interaction networks were generated with STRING
9.159 and visualized with Cytoscape 3.2.0.60 Biological processes were
analyzed with ClueGo 2.1.5.61
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